Cardiovascular risks associated with protease inhibitors for the treatment of HIV

References

• Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–248.
   PubMed Web of Science ®Google Scholar
• Van Sighem A, Gras L, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24(10):1527–1535.
   PubMed Web of Science ®Google Scholar
• Teeraananchai S, Kerr SJ, Amin J, et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2018;18(4):256–266.
   Web of Science ®Google Scholar
• Triant V, Lee L, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–2512.
   PubMed Web of Science ®Google Scholar
• Chow FC, Regan S, Feske S, et al. Comparison of Ischemic Stroke Incidence in HIV-Infected and Non-HIV-infected patients in a u.s. health care system. J Acquir Immune Defic Syndr. 2012;60(4):351–358.
   PubMed Web of Science ®Google Scholar
• Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453–468.
   PubMed Web of Science ®Google Scholar
• Boccara F, Mary-Krause M, Teiger E, et al. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. Eur Heart J. 2011;32(1):41–50.
   PubMed Web of Science ®Google Scholar
• Ryom R, Mocroft M, Kirk O, et al. Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: the D:A:D Study. J Infect Dis. 2016;214(8):1212–1220.
   PubMed Web of Science ®Google Scholar
• Rasmussen LD, Helleberg M, May MT, et al. Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. Clin Infect Dis. 2015;60(9):1415–1423.
   PubMed Web of Science ®Google Scholar
• Hunt PW. “HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012;9(2):139–147.
   PubMed Web of Science ®Google Scholar
• Zanni MV, Schouten J, Grinspoon SK, et al. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol. 2014;11(12):728–741.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: a: d study: a multi-cohort collaboration. Lancet. 2008;371:1417–1426.
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, et al. “Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men Commentary. AIDS. 2003;17(17):2479–2486.
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735.
   PubMed Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus–infected patients a case-control study nested within the french hospital database on HIV ANRS Cohort CO4. Antiretroviral Drugs, Risk of MI, and HIV. Arch Intern Med. 2010;170(14):1228–1238.
   PubMedGoogle Scholar
• Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189(6):1056–1074.
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14(1):51–57.
   PubMed Web of Science ®Google Scholar
• Worm SW, Sabin CA, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318–330.
   PubMed Web of Science ®Google Scholar
• Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1 – infected Patients: the MaxCmin1 Trial. JID. 2003;188(5):635–642.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323–332.
   PubMed Web of Science ®Google Scholar
• Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial *. HIV Med. 2013;14(1):49–59.
   PubMed Web of Science ®Google Scholar
• Hanna DB, Ramaswamy C, Kaplan RC, et al. Trends in cardiovascular disease mortality among persons with HIV in New York City, 2001-2012. Clin Infect Dis. 2016;63(8):1122–1129.
   PubMed Web of Science ®Google Scholar
• Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117(2):214–220.
   PubMed Web of Science ®Google Scholar
• Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between hiv-infected and uninfected individuals: the age HIV cohort study. Clin Infect Dis. 2014;59(12):1787–1797.
   PubMed Web of Science ®Google Scholar
• Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–818.
   PubMed Web of Science ®Google Scholar
• Bavinger C, Bendavid E, Niehaus K, et al. Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: a Systematic Review. PLoS One. 2014;8(3):e59551.
   Web of Science ®Google Scholar
• Lundgren JD, Mocroft A, Ryom L. Contemporary protease inhibitors and cardiovascular risk. Curr Opin Infect Dis. 2018;31(1):8–13.
   PubMed Web of Science ®Google Scholar
• Triant VA, Siedner MJ. Darunavir and Cardiovascular Risk: evaluating the Data to Inform Clinical Care. J Infect Dis. 2020;221(4):498–500.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Advances in pharmacology: Antiviral agents. Vol. 67, page 328. Academic Press, Elsevier Inc. (USA; UK, the Netherlands). All rights reserved; Copyright © 2013.
   Google Scholar
• Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients : the MaxCmin2 trial. Antivir Ther. 2005;10(6):735–743.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society guidelines 2020. [cited 2020 Nov 10]. Available at: https://www.eacsociety.org/files/guidelines-10.1_5.pdf
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and adolescents, IDSA Guidelines for the use of Antiretroviral agents in adults and adolescents with HIV. [cited 2020 Nov 10]. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf
   Google Scholar
• WHO, Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of hiv: interim guidelines” supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection . geneva: world Health Organization; 2018 (WHO/CDS/HIV/18.51). Licence: CC BY-NC-SA 3.0 IGO, [cited 2020 Nov 10]. Available at: https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51
   Google Scholar
• Hsue PY, Kamini G, Erickson S, et al. Clinical Features of Acute Coronary Syndromes in Patients With Human Immunodeficiency Virus Infection. Circulation. 2004;109(3):316–319.
   PubMed Web of Science ®Google Scholar
• Knudsen A, Mathiasen AB, Worck RH, et al. Angiographic Features and Cardiovascular Risk Factors in Human Immunodeficiency Virus-Infected Patients With First-Time Acute Coronary Syndrome. Am J Cardiol. 2013;111(1):63–67.
   PubMed Web of Science ®Google Scholar
• Post WS, Budoff M, Kingsley L, et al. HIV Infection and Subclinical Coronary Atherosclerosis. Ann Intern Med. 2014;160(7):458–467.
   PubMed Web of Science ®Google Scholar
• Tarr PE, Ledergerber B, Calmy A, et al. Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. Eur Heart J. 2018;39(23):2147–2154.
   PubMed Web of Science ®Google Scholar
• Zanni M, Abbara S, Lo J, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS. 2013;27(8):1263–1272.
   PubMed Web of Science ®Google Scholar
• Gutierrez J, Goldman J, Dwork AJ, et al. Brain arterial remodeling contribution to nonembolic brain infarcts in patients with HIV. Neurology. 2015;85(13):1139–1145.
   PubMed Web of Science ®Google Scholar
• Chow FC, Boscardina JW, Mills C, et al. Relationship between HIV infection, antiretroviral therapy, inflammatory markers and cerebrovascular endothelial function among adults in urban China. J. Acquir. Immune Defic. Syndr. AIDS 2016;30:45–55.
   Google Scholar
• Hanna DB, Post WS, Deal JA, et al. HIV infection is associated with progression of subclinical carotid atherosclerosis. Clin Infect Dis. 2015;61(4):640–650.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Delaney JAC, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23(14):1841–1849.
   PubMed Web of Science ®Google Scholar
• González-Cordón A, Doménech M, Camafort M, et al. Subclinical cardiovascular disease in patients starting contemporary protease inhibitors. HIV Med. 2018;19(7):497–503.
   Web of Science ®Google Scholar
• Stein JH, Brown TT, Ribaudo HJ, et al. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS. 2013;27(6):929–937.
   PubMed Web of Science ®Google Scholar
• Sankatsing RR, Wit FW, Vogel M, et al. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors. Atherosclerosis. 2009;202(2):589–595.
   PubMed Web of Science ®Google Scholar
• Maggi P, Bellacosa C, Leone A, et al. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: comparison of three different regimens - PREVALEAT II cohort. Atherosclerosis. 2017;263:398–404.
   PubMed Web of Science ®Google Scholar
• De Saint-Martin L, Bressollette L, Perfezou P, et al. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort. AIDS. 2010;24 (18):2797–2801.
   Web of Science ®Google Scholar
• Stein JH, Ribaudo HJ, Hodis HN, et al., A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015;29(14):1775–1783.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Tran TTT, Brown TT, et al., Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness : ACTG 5260s. Antivir Ther. 2017;22(2):113–126.
   PubMed Web of Science ®Google Scholar
• Baker JV, Sharma S, Achhra AC, et al. Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity : a Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial. OFID. 2016;3:1–8.
   Google Scholar
• Nolte JE, Neumann T, Manne JM, et al. Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men. Eur J Prev Cardiol. 2014;21(8):972–979.
   PubMed Web of Science ®Google Scholar
• Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014;7(10):1025–1038.
   PubMed Web of Science ®Google Scholar
• Thomas GP, Li X, Post WS, et al. Associations between antiretroviral use and subclinical coronary atherosclerosis. AIDS.2016;30(16):2477–2486.
   Google Scholar
• Kovari H, Calmy A, Doco-Lecompte T, et al. Antiretroviral drugs associated with subclinical coronary artery disease in the Swiss Human Immunodeficiency Virus Cohort study. Clin Infect Dis. 2020;70(5):884–889.
   PubMed Web of Science ®Google Scholar
• Vos AG, Idris NS, Barth RE, et al., Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection A Systematic Review . PLoS One. 2016;11(1):e0147484.
   PubMed Web of Science ®Google Scholar
• Dentone C, Di Biagio A, Cozzi Lepri A, et al. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. HIV Clin Trials. 2018;19(4):158–162.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Tran TTT, Stein JH, et al., Changes in Inflammation and Immune Activation with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis. 2015;61(4):651–660.
   PubMed Web of Science ®Google Scholar
• Martínez E, Gonzalez-Cordon A, Ferrer E, et al., Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Med.2014; 15(6):330–338.
   PubMed Web of Science ®Google Scholar
• Martinez E, Gonzalez-Cordon A, Ferrer E, et al., Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: a Randomized Clinical Trial. Clin Infect Dis.2015; 60(5):811–820.
   PubMed Web of Science ®Google Scholar
• Saumoy M, Ordonez-Llanos J, Martínez E, et al., Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. J Antimicrob Chemother.2015; 70(4):1130–1138.
   PubMed Web of Science ®Google Scholar
• Gatell JM, Assoumou L, Moyle G, et al., Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96-week results of the NEAT022 study. Clin Infect Dis. 2019; 68(4):597–606.
   PubMed Web of Science ®Google Scholar
• Molina JM, Clotet B, van Lunzen J, et al., Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015; 2(4):e127–36.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Na LH, Landovitz RJ, et al., Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60(12):1842–1851.
   PubMed Web of Science ®Google Scholar
• Mena A, Clavero E, Díaz-Díaz J, et al. Similar plasma lipidomic profile in people living with HIV treated with a darunavir-based or an integrase inhibitor-based antiretroviral therapy. Nature Sci Rep. 2019;9:17184.
   PubMed Web of Science ®Google Scholar
• Eron J, Orkin C, Cunningham D, et al. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically suppressed adults living with HIV-1. Antivir Res. 2019;170:104543.
   PubMed Web of Science ®Google Scholar
• Den Ruijter PS, Peters SAE, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012;308(8):796–803.
   PubMed Web of Science ®Google Scholar
• Ryom L, Lundgren JD, El-Sadr W, et al., Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018(6): e291–e300. 2018.
   Google Scholar
• d'Arminio Monforte A, Reiss P, Ryom L, et al., Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS. 2013;27(3):407–415. .
   PubMed Web of Science ®Google Scholar
• Costagliola D, Potard V, Lang S, et al. Is the Risk of Myocardial Infarction in People with Human Immunodeficiency Virus (HIV) Associated with Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV. J Infect Dis. 2020;221(4):516–522.
   Google Scholar
• Antinori A, Rusconi S, Gianotti N, et al. Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study. Drug Des Devel Ther. 2019;13:1667–1685.
   PubMed Web of Science ®Google Scholar
• Diaz CM, Segura ER, Luz PM, et al. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. BMC Infect Dis. 2016;16(1):1–13.
   PubMedGoogle Scholar
• Li M, Chan WW, Zucker SD. Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV. J Am Heart Assoc. 2020;9(19):e016310.
   PubMed Web of Science ®Google Scholar
• Opsomer M, Dimitrova D, Verspeelt J, et al., Evaluation of Cardiovascular Disease Risk in HIV ‑ 1 – infected Patients Treated with Darunavir. Drugs R D. 2018;18(3):199–210.
   PubMed Web of Science ®Google Scholar
• Antinori A, Lazzarin A, Uglietti A, et al. Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials. Nature Sci. Rep. 2018;8:5288.
   PubMed Web of Science ®Google Scholar
• Chow D, Shikuma D, Ritchings C, et al. Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: a Systematic Review. Infect Dis Ther. 2016;5(4):473–489.
   PubMed Web of Science ®Google Scholar
• Lafleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 2017;31(15):2095–2106.
   PubMed Web of Science ®Google Scholar
• Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem. 2000;46(11):1723–1727.
   PubMed Web of Science ®Google Scholar
• Muccini C, Galli L, Poli A, et al. Hyperbilirubinemia is associated with a decreased risk of carotid atherosclerosis in HIV-infected patients on virological suppression. J Acquir Immune Defic Syndr. 2018;79(5):617–623.
   PubMed Web of Science ®Google Scholar
• Marconi VC, Duncan MS, So-Armah K, et al., Bilirubin is inversely associated with cardiovascular disease among HIV-positive and HIV-negative individuals in VACS (Veterans Aging Cohort Study). J Am Heart Assoc. 2018;7(10):1–12.
   Web of Science ®Google Scholar
• Crane HM, Paramsothy P, Drozd DR, et al. Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States. J Acquir Immune Defic Syndr. 2019;81(5):e141–e147.
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95(14):8170–8174
   PubMed Web of Science ®Google Scholar
• Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert’s disease and atazanavir: from phenotype to UDP- glucuronosyltransferase haplotype. Hepatology. 2006;44(5):1324–1332.
   PubMed Web of Science ®Google Scholar
• D’Avolio A, Simiele M, Calcagno A, et al. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. J Antimicrob Chemother. 2013;68(4):907–910.
   PubMed Web of Science ®Google Scholar
• Santos JR, Curran A, Navarro-Mercade J, et al. Simplification of antiretroviral treatment from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety in routine clinical practice. AIDS Res Hum Retroviruses. 2019;35(6):513–518.
   PubMed Web of Science ®Google Scholar
• Echeverría P, Bonjoch A, Puig J, et al. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. HIV Med. 2017;18(10):782–786.
   PubMed Web of Science ®Google Scholar
• Trentalange A, Polifroni C, Carcieri C, et al. Switching from atazanavir/ritonavir (ATV/RTV) to ATV/cobicistat is associated with decrease in plasma lipids and liver fibrosis. Unit of Infectious Diseases, Department of Medical Sciences, University of Torino Poster presentation 111 at HIV Glasgow. Scotland: Glasgow; 2018 Oct 28-31.
   Google Scholar
• Anuurad E, Bremer A, Berglund L. HIV protease inhibitors and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):478–485.
   PubMedGoogle Scholar
• Reyskens KMSE, Faadiel Essop M. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin–proteasome system. Biochim. Biopphysica Acta. 2014;1842(2):256–268.
   PubMed Web of Science ®Google Scholar
• Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol Rev. 2006;86(4):1133–1149.
   PubMed Web of Science ®Google Scholar
• Zhou H, Pandak WM, Lyall L, et al. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol. 2005;68(3):690–700.
   PubMed Web of Science ®Google Scholar
• Badley AD, Pilon A, Landay A, et al. Review article Mechanisms of HIV-associated lymphocyte apoptosis. Blood. 2000;96:2951–2964.
   PubMed Web of Science ®Google Scholar
• Zha BS, Wan X, Zhang X, et al. HIV Protease Inhibitors Disrupt Lipid Metabolism by Activating Endoplasmic Reticulum Stress and Inhibiting Autophagy Activity in Adipocytes. PLoS One. 2013;8(3):e59514.
   PubMed Web of Science ®Google Scholar
• Zhou H, Jarujaron S, Gurley EC, et al. HIV protease inhibitors increase TNF-α and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR. Atherosclerosis. 2007;195(1):e134–e143.
   PubMedGoogle Scholar
• Chen L, Jarujaron S, Wua X, et al. HIV protease inhibitor lopinavir-induced TNF-α and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages. Biochem Pharmacol. 2009;78(1):70–77.
   PubMed Web of Science ®Google Scholar
• Wilson ME, Sengoku T, Allred KF. Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir. J Cell Biochem. 2008;103(5):1598–1606.
   PubMed Web of Science ®Google Scholar
• Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages Find the latest version : atherosclerotic lesion formation independent of dyslipidemia. J Clin Invest. 2003;111(3):389–397.
   PubMed Web of Science ®Google Scholar
• Boccara F, Auclair M, Cohen A, et al. HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther. 2010;15(3):363–375.
   PubMed Web of Science ®Google Scholar
• Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104(3):257–262.
   PubMed Web of Science ®Google Scholar
• Auclair M, Afonso P, Capel E, et al. Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin. Antivir. Ther. 2014;19(8):773–782.
   PubMed Web of Science ®Google Scholar
• O’Halloran JA, Dunne E, Gurwith MMP, et al. The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection. HIV Med. 2015;16(10):608–619.
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Ryom L, Smith C, et al., An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol.2016; 23(2):214–222.
   PubMed Web of Science ®Google Scholar
• Ruellan AL, Bourneau-Martin D, Joyau C, et al. Assessment of drug–drug interaction in an elderly human immunodeficiency virus population: comparison of 3 expert databases. Br J Clin Pharmacol. 2020;87(3):1194–1202.
   PubMed Web of Science ®Google Scholar
• Socio DE, Ricci E GV, Parruti G, et al. Statins and Aspirin use in HIV‑infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV‑HY study. Infection. 2016;44(5):589–597.
   PubMed Web of Science ®Google Scholar
• Potard V, Canestri A, Gallien S, et al. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France. J Antimicrob Chemother. 2019;74(11):3305–3314.
   PubMed Web of Science ®Google Scholar
• Capetti AF, De Socio GV, Cossu MV, et al. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials. 2018;19(6):242–248.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020;71(6):1379–1389
   PubMed Web of Science ®Google Scholar
• Pulido F, Ribera E, Lagarde M, et al. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression. Clin Infect Dis. 2017;65(12):2112–2118.
   PubMed Web of Science ®Google Scholar
• Liew Z, Hill A, Simmons B. Dual therapy with PI/r+3TC or PI/r+TDF shows non-inferior HIV RNA suppression and lower rates of discontinuation for adverse events, versus triple therapy. Meta-analysis of seven randomised trials in 1624 patients. Imperial College London. Oral presentation 114 at HIV Glasgow. Scotland: Glasgow; 2018 Oct 28-31.
   Google Scholar
• Castagna A, Rusconi S, Gulminetti R, et al. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. AIDS. 2019;33(7):1256–1260.
   PubMed Web of Science ®Google Scholar
• Greenberg L, Ryom L, Neesgaard B, et al. Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. Clin Infect Dis. 2020 Dec;23:ciaa1878.
   Google Scholar
• The RESPOND Study group. How to RESPOND to Modern Challenges for People Living with HIV: a Profile for a New Cohort Consortium. Microorganisms. 2020;8(8):1164.
   Web of Science ®Google Scholar